Show an ad over header. AMP

I am the FIRST

The two-sided risks of research on viruses

The revival of the "lab leak" theory of COVID-19 — that it started with a virus that originated in a laboratory — is drawing new attention to the dangers of scientific experiments that enhance pathogens to study them.

Why it matters: So-called "gain-of-function" research can be invaluable in predicting future pandemic threats, but it can also generate risks by introducing new, potentially more dangerous viruses.

Driving the news: Last week, a group of leadingresearchers called for a renewed investigation into the origins of COVID-19 in a letter published in the journal Science.

  • It was the most prominent sign that the initial explanation for the emergence of SARS-CoV-2 — that it spilled over from an animal source — is coming into doubt.
  • There's no bulletproof evidence for either hypothesis yet, and the basic fact that past outbreaks have repeatedly been started by animal spillovers puts a higher burden of proof on the possibility of a lab leak.
  • But as Harvard epidemiologist Marc Lipsitch — a signatory to the Science letter — told WBUR last weekend, "If this did come from a laboratory, then that really has implications for the kind of work that we should be doing and the kind of safeguards that need to be in place if we're going to do that work."

How it works: Gain-of-function research involves purposefully enhancing pathogens in a lab to better understand them.

  • Proponents of such research argue it is one of the best ways to prepare for future pandemics, allowing scientists to identify potential genetic changes in pathogens that could make them more transmissible or virulent, and to design and stockpile vaccines and treatments.
  • Opponents say the research itself poses an unacceptable risk by bringing into the world more dangerous viruses that wouldn't have otherwise existed — potentially triggering pandemics if they escape in a lab accident.

The backstory: Concerns around gain-of-function research, prompted by work with the H5N1 avian flu virus, led the National Institutes of Health to put a funding pause in 2014 on such studies involving dangerous viruses like flu or SARS. The pause was lifted three years later after the creation of an oversight framework.

Like all low-probability/high-consequence events, hard data on both the true risks and benefits of gain-of-function research is hard to come by, which makes it difficult to estimate the scale of the threat.

  • In 2014, Lipsitch and Tom Inglesby of the Johns Hopkins Center for Health Security estimated the risk of a pandemic caused by an accidental release from a high-security biolab doing such work with a transmissible flu virus over a single year at between 1 in 10,000 and 1 in 100,000.
  • At the lower level, that's less than the expected risk of a random pedestrian dying in a traffic accident in a given year. Should a pandemic spill out of a lab, however, the result wouldn't be one person dying, but potentially millions.

Yes, but: An accidental human-made pandemic requires not just the creation of a more dangerous virus in a lab, but a safety breakdown that allows it to escape — and some experts argue that gain-of-function skeptics have overestimated the likelihood of such safety lapses.

  • Outlawing or even more tightly regulating gain-of-function work would carry unknown risks itself, as we might lose out on research that could protect us against future pandemics.

What's next: Barring a sudden shift toward transparency by the Chinese government, we may never know conclusively the true origins of COVID-19. But the risk from human-made pathogens is almost surely growing.

  • More labs around the world are pursuing potentially risky virus research, and some of it is likely being done in less-than-optimal safety conditions — as may have been the case at the Wuhan Institute of Virology.
  • New tools that make it cheaper and easier to write gene sequences raise the risk as well, prompting California to move on a bill this week that would require DNA synthesis companies to adopt what are currently voluntary protocols to screen for dangerous sequences.
  • Whatever the ultimate results of the COVID-19 investigation, researchers should double down on lab safety, which has too often been an afterthought.

The bottom line: Should we discover that COVID-19 originated in research — however well-intentioned — a recent boost in public support for science could evaporate, which might be the greatest risk of all.

GM boosts investment in electric, autonomous vehicles by $8 billion

General Motors plans to boost its cumulative investment in electric and autonomous vehicles to $35 billion from 2020-2025, a significant jump from a $27 billion target.

Driving the news: GM said this morning that the initiative will include building two new battery cell manufacturing plants in addition to the two already under construction in Tennessee and Ohio.

Keep reading... Show less

Biden administration buys 200 million additional doses of Moderna’s COVID vaccine

The Biden administration has purchased an additional 200 million doses of Moderna’s coronavirus vaccine, the biotech company announced Wednesday.

Why it matters: Moderna says the additional doses could be used to vaccinate children or — if necessary — as a booster shot.

Keep reading... Show less

Live updates: Biden and Putin land in Geneva ahead of summit

President Biden is set to meet with Russian President Vladimir Putin in Geneva for five hours of talks on Wednesday, a highly anticipated summit that comes as both sides say U.S.-Russia relations have sunk to a new post-Cold War low.

The latest: Putin arrived in Geneva shortly before 7 a.m. ET and traveled via motorcade to Villa La Grange, a mansion set in a 75-acre park overlooking Lake Geneva. Biden arrived at around 7:20 a.m. ET. The two leaders are expected to take a photo with Swiss President Guy Parmelin before the meeting begins.

Keep reading... Show less

Biden-Putin summit: What to expect when you're not expecting much

After a bitter blast from Putin and tough talk from Biden, both sides agree: Don't count on much from Wednesday's summit between President Biden and Russian President Vladimir Putin.

What they're saying: "We’re not expecting a big set of deliverables out of this meeting," a senior Biden administration official told reporters on Air Force One from Brussels to Geneva. "No breaking of bread."

Keep reading... Show less

Florida's early reopening could make it a business travel mecca

As post-pandemic business travel comes back, experts say Florida's reopening policies should allow it to lock in a significant share of returning corporate events and meetings.

Why it matters: There's a lot of money to be made — with a lot of people itching to travel — after the sector lost $97 billion in spending last year, according to a new Tourism Economics analysis by the U.S. Travel Association.

Keep reading... Show less

There isn’t a worker shortage in the U.S. — there’s been a worker awakening

Many politicians, pundits and business owners have said pandemic-era enhanced unemployment benefits are keeping would-be workers at home. But that's a much too simplistic explanation of today's employment situation.

The big picture: Many hard-hit sectors are rebounding faster than anecdotal evidence would suggest. And when jobs are hard to fill, a broader worker awakening over the past year is part of the reason.

Keep reading... Show less

Biden's surprise pick for FTC chair, a leading tech critic, is already rocking boats

By naming tech critic Lina Khan to chair the Federal Trade Commission Tuesday, the White House made clear it is dead serious about antitrust enforcement and other measures to rein in Google, Facebook, Apple and Amazon.

The intrigue: By naming Khan FTC chair just hours after the Senate confirmed her appointment as one of five commissioners at the agency, the White House took both the industry and many D.C. insiders by surprise.

Keep reading... Show less

MedPAC says higher prices drove up Medicare drug spending

The amount Medicare spent on drugs that are dispensed at pharmacies increased 26% from 2013 through 2018, members of the Medicare Advisory Payment Commission wrote in their new annual report.

Why it matters: MedPAC members put the spotlight on pharmaceutical companies, attributing "nearly all of the growth ... to higher prices rather than an increase in the number of prescriptions filled by beneficiaries."

Keep reading... Show less



Get Goodhumans in your inbox

Most Read

More Stories